Mobilised peripheral blood cells - Cellect Biotechnology

Drug Profile

Mobilised peripheral blood cells - Cellect Biotechnology

Alternative Names: ApoGraft™; Mobilised peripheral blood cells - Cellect Biotechnology; Mobilised peripheral blood product - Cellect Biotechnology

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellect Biotechnology
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Graft-versus-host disease

Most Recent Events

  • 05 Sep 2017 Mobilised peripheral blood cells receives Orphan Drug status for Graft-versus-host disease (Prevention) in USA
  • 03 Apr 2017 Cellect Biotechnology receives a notice of intention to grant for a patent covering a key method of treatment the the European Patent Office
  • 22 Feb 2017 Immunogenicity data from a clinical trial in Healthy volunteers released by Cellect Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top